Nisin

Nisin is produced by Lactococcus lactis and belongs to the lantibiotic family, defined by thioether-bridged lanthionine and methyllanthionine rings introduced after translation. Its N-terminal rings A and B form a cage around the pyrophosphate of lipid II, the universal peptidoglycan precursor, with nanomolar affinity — a binding mode structurally distinct from vancomycin's. That alone halts cell wall synthesis. The C-terminal region then inserts into the membrane and, using lipid II as an anchor, eight nisin molecules and four lipid II molecules assemble a stable pore. The dual mechanism explains why nisin is active at nanomolar concentrations where most antimicrobial peptides need micromolar, and why resistance is uncommon after seventy years of use in food. It is destroyed by gastric acid and proteases, has poor activity against gram-negatives without an outer-membrane permeabiliser, and is not systemically bioavailable — the reasons it has stayed a preservative rather than becoming an antibiotic.

Targets: Lipid II pyrophosphate, Peptidoglycan synthesis, Bacterial cytoplasmic membrane

• · Used at roughly 2.5-12.5 mg per kilogram of food, mainly in processed cheese, canned goods and dairy to suppress Clostridium botulinum and Listeria. The JECFA acceptable daily intake is 0-2 mg/kg body weight. This is the only use with genuine regulatory standing.
• · Human data are minimal. Studies have used purified nisin preparations for oral and gut-directed effects, but no dose has been validated for treating an infection. Anyone quoting a milligram protocol for nisin as an antibiotic is extrapolating from food science.
• · Nisin has been studied in mouthwashes, dental gels for periodontal pathogens, and mastitis preparations in dairy cattle. Small human periodontal studies show plaque and gingival index improvements; the evidence is preliminary.

Work out your exact syringe units →

• uncommonGastrointestinal upset at high oral doses— Reported in some investigational settings using purified nisin well above dietary exposures.
• uncommonShifts in gut gram-positive flora— Theoretical and demonstrated in animal models with high-dose purified nisin; the clinical significance in humans is unknown.
• rareNone established at food-preservative exposures— Seventy years of dietary use across dozens of countries with no consistent adverse signal. JECFA and EFSA have both reviewed it and set a generous acceptable daily intake.
• rareHypersensitivity— Very rarely reported; commercial preparations contain milk-derived solids, which matters for milk-protein allergy.

• Milk protein allergy, where commercial nisin preparations containing milk solids should be avoided.
• Not a substitute for an antibiotic in any established infection — there is no approved therapeutic indication.
• Not for injection; nisin has never been developed or tested as a parenteral agent.

• synergyEDTA and other chelators — Chelators permeabilise the gram-negative outer membrane and extend nisin's spectrum beyond gram-positives. This is a standard food-science combination.
• synergyvancomycin — Both target lipid II at different sites, and synergy has been demonstrated in vitro including against vancomycin-resistant strains. It has not been tested clinically.
• cautionprobiotics — Nisin kills gram-positive bacteria, including many lactobacilli and bifidobacteria in probiotic products. Taking them together is somewhat self-defeating.

• · No monitoring is applicable to dietary exposure.
• · For investigational oral use, symptom-based follow-up only; there is no validated biomarker.

Approved as a food preservative (E234) in the EU, GRAS in the US, and permitted in most food codes worldwide. Not approved as a therapeutic agent anywhere. Sold as a dietary supplement in some markets on the strength of its food-additive status.

• Hsu et al., NMR structure of the lipid II-nisin complex and the pyrophosphate cage binding motif (preclinical)
• JECFA and EFSA safety evaluations of nisin as a food additive (guideline)
• Shin et al., biomedical applications of nisin (review)

A lantibiotic - a ribosomally synthesised peptide bearing lanthionine thioether rings introduced post-translationally. It binds lipid II, both blocking cell wall synthesis and using the bound lipid II as a docking module to assemble pores. Hitting one target two ways is why resistance is rare despite decades of use.

The recurring misunderstanding is treating a food preservative as a therapeutic. Nisin has been in the food supply as E234 for decades with an excellent safety record, and that record is a consequence of it being destroyed in the gut. Eating more of it does not produce an antibiotic effect anywhere but the gut lumen.

• Lipid II — High; dual cell-wall and pore-forming action

  Blocks peptidoglycan synthesis and permeabilises the membrane

Immediate where applied; no systemic exposure.

• ?Engineered nisin variants for systemic use are an active research area with no clinical product.